Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Provention Bio, Inc. PRVB
$24.98
На 18:01, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
2375415796.00000000
-
week52high
25.00
-
week52low
3.19
-
Revenue
12895000
-
P/E TTM
-17
-
Beta
2.46036900
-
EPS
-1.52000000
-
Last Dividend
0.00000000
-
Next Earnings Date
02 авг 2023 г. в 12:30
Описание компании
Provention Bio, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics and solutions to intercept and prevent immune-mediated diseases. Its products candidates include PRV-031 teplizumab and monoclonal antibodies (mAb) that is in Phase III clinical trial for the interception of type one diabetes (T1D); PRV-3279, which has completed Phase Ib clinical trial for the treatment of lupus; PRV-101, a coxsackie virus B (CVB) vaccine for the prevention of acute CVB infections and onset of T1D; and PRV-015, which is in phase IIb clinical trial for the treatment of gluten-free diet non-responding celiac disease. The company has a license and collaboration agreement with Amgen Inc. for PRV-015, a novel anti-IL-15 monoclonal antibody being developed for the treatment of gluten-free diet non-responsive celiac disease; and a strategic collaboration with Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. to develop and commercialize PRV-3279, a bispecific antibody-based molecule targeting the B cell surface proteins CD32B and CD79B in Greater China. Provention Bio, Inc. was incorporated in 2016 and is headquartered in Red Bank, New Jersey.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Chardan Capital | Buy | Buy | 05 авг 2022 г. |
| HC Wainwright & Co. | Buy | Buy | 11 июл 2022 г. |
| Oppenheimer | Outperform | Outperform | 06 авг 2021 г. |
| HC Wainwright & Co. | Buy | Buy | 06 авг 2021 г. |
| Chardan Capital | Buy | Buy | 13 апр 2021 г. |
| Jefferies | Buy | 20 сент 2022 г. | |
| Jefferies | Buy | Buy | 07 окт 2022 г. |
| Chardan Capital | Buy | Buy | 04 ноя 2022 г. |
| SVB Leerink | Outperform | Outperform | 21 ноя 2022 г. |
| Chardan Capital | Buy | Buy | 21 ноя 2022 г. |
| Oppenheimer | Outperform | Outperform | 18 ноя 2022 г. |
| Jefferies | Buy | Buy | 18 ноя 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Leon Francisco | D | 318088 | 24015 | 18 янв 2023 г. |
| Leon Francisco | D | 1573000 | 24015 | 18 янв 2023 г. |
| Leon Francisco | A | 1597015 | 24015 | 18 янв 2023 г. |
| Palmer Ashleigh | D | 517555 | 24165 | 18 янв 2023 г. |
| Palmer Ashleigh | D | 2570050 | 24165 | 18 янв 2023 г. |
| Palmer Ashleigh | A | 2594215 | 24165 | 18 янв 2023 г. |
| Sessa Capital (Master), L.P. | D | 11879023 | 3000000 | 18 янв 2023 г. |
| Palmer Ashleigh | A | 700000 | 700000 | 17 янв 2023 г. |
| Vogel Justin | A | 84000 | 84000 | 10 янв 2023 г. |
| Yi Miyoko Christina | A | 187000 | 187000 | 10 янв 2023 г. |
Новостная лента
The 5 Best- and Worst-Performing Mid-Cap Stocks in March 2023
24/7 Wall Street
10 апр 2023 г. в 22:58
March was a good month for the stock market, with the S&P 500 gaining about 3.5%.
Why Provention Bio Stock Skyrocketed 256% This Week
The Motley Fool
16 мар 2023 г. в 16:56
Sanofi plans to acquire Provention Bio for around $2.9 billion. The deal will add Provention's type 1 diabetes drug Tzield to Sanofi's lineup.
Provention (PRVB) Skyrockets 260% on Buyout Offer From Sanofi
Zacks Investment Research
14 мар 2023 г. в 13:44
Provention Bio (PRVB) to be acquired by pharma-giant Sanofi (SNY) for $2.9 billion. The transaction is likely to close by second-quarter 2023.
This biopharma stock jumped over 250% on Monday: what happened?
Invezz
13 мар 2023 г. в 20:22
Shares of Provention Bio Inc (NASDAQ: PRVB) more than tripled on Monday after Sanofi S.A. (EPA: SAN) confirmed plans of buying the biopharmaceutical company that focused on autoimmune diseases.
Monday Merger Mania Just Made These 2 Biotech Stocks Big Winners
The Motley Fool
13 мар 2023 г. в 19:15
Markets were mixed on a volatile day on Wall Street. Sanofi offered to buy Provention Bio at a price more than triple where the stock closed Friday.